Literature DB >> 6693640

Prognostic importance of digitalis after acute myocardial infarction.

E B Madsen, E Gilpin, H Henning, S Ahnve, M LeWinter, J Mazur, R Shabetai, D Collins, J Ross.   

Abstract

Because previous reports have suggested that digitalis administration may lead to increased mortality after hospital discharge for acute myocardial infarction, the independent importance of digitalis therapy in long-term prognosis after acute myocardial infarction was investigated by analyzing 1,599 patients after definite myocardial infarction. After hospital discharge, mortality rate for the entire group at 4 months was 7.7% and after 1 year 14.2%. At discharge, 36.6% of the patients were taking digitalis. Compared with those not taking digitalis, those taking digitalis had more historical risk factors and a higher incidence of important clinical prognostic variables during the hospitalization. Their cardiac mortality rate after 4 months and 1 year (12.5 and 22.4%, respectively) was significantly higher than that of patients not taking digitalis (5.0 and 9.6%, respectively). Mortality was higher for patients taking digitalis whether or not they had congestive heart failure during hospitalization. However, in a multivariate Cox analysis for 1 year outcome, neither digitalis nor any other medication variable displaced the important clinical variables of age, congestive heart failure during the hospitalization, previous myocardial infarction, maximal heart rate during the hospitalization and previous angina. Quinidine and digitalis at discharge were selected sixth and seventh (not significant) by the analysis. It is concluded that digitalis therapy at discharge after myocardial infarction was not an independent predictor of late mortality in these patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693640     DOI: 10.1016/s0735-1097(84)80243-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

Review 1.  Serum concentration monitoring of cardiac glycosides. How helpful is it for adjusting dosage regimens?

Authors:  R J Dobbs; C J O'Neill; A A Deshmukh; P W Nicholson; S M Dobbs
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Digoxin after myocardial infarction. Does it have a role?

Authors:  G D Johnston
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

3.  Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium.

Authors:  R Padrini; M Panfili; G Magnolfi; D Piovan; D Casarotto; M Ferrari
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 4.  Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment?

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

5.  Five-year mortality after acute myocardial infarction in relation to previous history, level of initial care, complications in hospital, and medication at discharge.

Authors:  J Herlitz; A Bång; M Sjölin; B W Karlson
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

6.  The mortality risk associated with digitalis treatment after myocardial infarction.

Authors:  A J Moss; J T Bigger; E Carleen; J L Fleiss; C L Odoroff; L Rolnitzky; T Therneau
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

Review 7.  Digitalis toxicity--turning over a new leaf?

Authors:  S J Bhatia
Journal:  West J Med       Date:  1986-07

8.  The future role of inotropic drugs.

Authors:  P A Poole-Wilson
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 9.  Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure.

Authors:  I Crozier; H Ikram
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

10.  Digoxin and mortality in survivors of acute myocardial infarction: observations in patients at low and intermediate risk. The SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial.

Authors:  J Leor; U Goldbourt; S Behar; V Boyko; H Reicher-Reiss; E Kaplinsky; B Rabinowitz
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.